Mylan Launches Generic Combivir In U.S - Quick Facts

(RTTNews) - Generic drug maker Mylan, Inc. (MYL) Monday announced the launch of its Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, which is the generic version of Viiv's Combivir, in the U.S. This follows the U.S. Food and Drug Administration or FDA's final approval of the Abbreviated New Drug Application of this product, to treat HIV-1 infection in combination with other antiretroviral or ARV agents. The product is expected to strengthen the company's growing ARV portfolio in the U.S. market. According to IMS Health, Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, had U.S. sales of about $118.5 million for the 12 months ended June 30, 2014.